Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas

Andrew Faramand, Hideyuki Kano, Ajay Niranjan, Stephen A. Johnson, Mohab Hassib, Kyung-Jae Park, Yoshio Arai, John C. Flickinger, L. Dade Lunsford

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To evaluate cranial nerve (CN) outcomes after primary stereotactic radiosurgery (SRS) for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. Methods: From our prospectively maintained database of 2022 meningioma patients who underwent Leksell stereotactic radiosurgery (SRS) during a 30-year interval, we found 98 patients with petroclival, 242 with cavernous sinus, and 55 patients with cerebellopontine angle meningiomas. Primary radiosurgery was performed in 245 patients. Patients included in this report had at least one CN deficit at the time of initial presentation and a minimum of 12 month follow up. Median age at the time of SRS was 58 years. Median follow up was 58 months (range 12–300 months), Median tumor volume treated with SRS was 5.9 cm3 (range 0.5–37.5 cm3), and median margin dose was 13 Gy (range 9–20Gy). Results: Tumor control was achieved in 229 patients (93.5%) at a median follow up of 58 months. Progression free survival rate (PFS) after SRS was 98.7% at 1 year, 96.4% at 3 years, 93.7% at 5 years, and 86.4% at 10 years Overall, 114 of the 245 patients (46.5%) reported improvement of CN function. Patients with CP angle meningiomas demonstrated lower rates of CN improvement compared to petroclival and cavernous sinus meningioma patients. Deterioration of CN function after SRS developed in 24 patients (10%). The rate of deterioration was 2.8% at 1 year, 5.2% at 3 years, and 8% at 10 years. Conclusion: Primary SRS provides effective tumor control and favorable rate of improvement of preexisting CN deficit.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalJournal of Neuro-Oncology
DOIs
Publication statusAccepted/In press - 2018 Apr 24

Fingerprint

Radiosurgery
Cranial Nerves
Skull Base
Meningioma
Cavernous Sinus
Cerebellopontine Angle
Tumor Burden
Disease-Free Survival
Neoplasms
Survival Rate
Databases

Keywords

  • Cranial nerve
  • Meningioma
  • Radiosurgery
  • Skull base

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas. / Faramand, Andrew; Kano, Hideyuki; Niranjan, Ajay; Johnson, Stephen A.; Hassib, Mohab; Park, Kyung-Jae; Arai, Yoshio; Flickinger, John C.; Lunsford, L. Dade.

In: Journal of Neuro-Oncology, 24.04.2018, p. 1-8.

Research output: Contribution to journalArticle

Faramand, A, Kano, H, Niranjan, A, Johnson, SA, Hassib, M, Park, K-J, Arai, Y, Flickinger, JC & Lunsford, LD 2018, 'Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas', Journal of Neuro-Oncology, pp. 1-8. https://doi.org/10.1007/s11060-018-2866-9
Faramand, Andrew ; Kano, Hideyuki ; Niranjan, Ajay ; Johnson, Stephen A. ; Hassib, Mohab ; Park, Kyung-Jae ; Arai, Yoshio ; Flickinger, John C. ; Lunsford, L. Dade. / Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas. In: Journal of Neuro-Oncology. 2018 ; pp. 1-8.
@article{02d7e87a470b467d88c8a100d4444850,
title = "Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas",
abstract = "Objective: To evaluate cranial nerve (CN) outcomes after primary stereotactic radiosurgery (SRS) for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. Methods: From our prospectively maintained database of 2022 meningioma patients who underwent Leksell stereotactic radiosurgery (SRS) during a 30-year interval, we found 98 patients with petroclival, 242 with cavernous sinus, and 55 patients with cerebellopontine angle meningiomas. Primary radiosurgery was performed in 245 patients. Patients included in this report had at least one CN deficit at the time of initial presentation and a minimum of 12 month follow up. Median age at the time of SRS was 58 years. Median follow up was 58 months (range 12–300 months), Median tumor volume treated with SRS was 5.9 cm3 (range 0.5–37.5 cm3), and median margin dose was 13 Gy (range 9–20Gy). Results: Tumor control was achieved in 229 patients (93.5{\%}) at a median follow up of 58 months. Progression free survival rate (PFS) after SRS was 98.7{\%} at 1 year, 96.4{\%} at 3 years, 93.7{\%} at 5 years, and 86.4{\%} at 10 years Overall, 114 of the 245 patients (46.5{\%}) reported improvement of CN function. Patients with CP angle meningiomas demonstrated lower rates of CN improvement compared to petroclival and cavernous sinus meningioma patients. Deterioration of CN function after SRS developed in 24 patients (10{\%}). The rate of deterioration was 2.8{\%} at 1 year, 5.2{\%} at 3 years, and 8{\%} at 10 years. Conclusion: Primary SRS provides effective tumor control and favorable rate of improvement of preexisting CN deficit.",
keywords = "Cranial nerve, Meningioma, Radiosurgery, Skull base",
author = "Andrew Faramand and Hideyuki Kano and Ajay Niranjan and Johnson, {Stephen A.} and Mohab Hassib and Kyung-Jae Park and Yoshio Arai and Flickinger, {John C.} and Lunsford, {L. Dade}",
year = "2018",
month = "4",
day = "24",
doi = "10.1007/s11060-018-2866-9",
language = "English",
pages = "1--8",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas

AU - Faramand, Andrew

AU - Kano, Hideyuki

AU - Niranjan, Ajay

AU - Johnson, Stephen A.

AU - Hassib, Mohab

AU - Park, Kyung-Jae

AU - Arai, Yoshio

AU - Flickinger, John C.

AU - Lunsford, L. Dade

PY - 2018/4/24

Y1 - 2018/4/24

N2 - Objective: To evaluate cranial nerve (CN) outcomes after primary stereotactic radiosurgery (SRS) for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. Methods: From our prospectively maintained database of 2022 meningioma patients who underwent Leksell stereotactic radiosurgery (SRS) during a 30-year interval, we found 98 patients with petroclival, 242 with cavernous sinus, and 55 patients with cerebellopontine angle meningiomas. Primary radiosurgery was performed in 245 patients. Patients included in this report had at least one CN deficit at the time of initial presentation and a minimum of 12 month follow up. Median age at the time of SRS was 58 years. Median follow up was 58 months (range 12–300 months), Median tumor volume treated with SRS was 5.9 cm3 (range 0.5–37.5 cm3), and median margin dose was 13 Gy (range 9–20Gy). Results: Tumor control was achieved in 229 patients (93.5%) at a median follow up of 58 months. Progression free survival rate (PFS) after SRS was 98.7% at 1 year, 96.4% at 3 years, 93.7% at 5 years, and 86.4% at 10 years Overall, 114 of the 245 patients (46.5%) reported improvement of CN function. Patients with CP angle meningiomas demonstrated lower rates of CN improvement compared to petroclival and cavernous sinus meningioma patients. Deterioration of CN function after SRS developed in 24 patients (10%). The rate of deterioration was 2.8% at 1 year, 5.2% at 3 years, and 8% at 10 years. Conclusion: Primary SRS provides effective tumor control and favorable rate of improvement of preexisting CN deficit.

AB - Objective: To evaluate cranial nerve (CN) outcomes after primary stereotactic radiosurgery (SRS) for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. Methods: From our prospectively maintained database of 2022 meningioma patients who underwent Leksell stereotactic radiosurgery (SRS) during a 30-year interval, we found 98 patients with petroclival, 242 with cavernous sinus, and 55 patients with cerebellopontine angle meningiomas. Primary radiosurgery was performed in 245 patients. Patients included in this report had at least one CN deficit at the time of initial presentation and a minimum of 12 month follow up. Median age at the time of SRS was 58 years. Median follow up was 58 months (range 12–300 months), Median tumor volume treated with SRS was 5.9 cm3 (range 0.5–37.5 cm3), and median margin dose was 13 Gy (range 9–20Gy). Results: Tumor control was achieved in 229 patients (93.5%) at a median follow up of 58 months. Progression free survival rate (PFS) after SRS was 98.7% at 1 year, 96.4% at 3 years, 93.7% at 5 years, and 86.4% at 10 years Overall, 114 of the 245 patients (46.5%) reported improvement of CN function. Patients with CP angle meningiomas demonstrated lower rates of CN improvement compared to petroclival and cavernous sinus meningioma patients. Deterioration of CN function after SRS developed in 24 patients (10%). The rate of deterioration was 2.8% at 1 year, 5.2% at 3 years, and 8% at 10 years. Conclusion: Primary SRS provides effective tumor control and favorable rate of improvement of preexisting CN deficit.

KW - Cranial nerve

KW - Meningioma

KW - Radiosurgery

KW - Skull base

UR - http://www.scopus.com/inward/record.url?scp=85045885528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045885528&partnerID=8YFLogxK

U2 - 10.1007/s11060-018-2866-9

DO - 10.1007/s11060-018-2866-9

M3 - Article

C2 - 29691775

AN - SCOPUS:85045885528

SP - 1

EP - 8

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -